Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities

doi:10.4254/wjh.v13.i11.1568

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5267)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

448

WORD

169

HTML

3084

Figures (1-5)

209

Tables (1-2)

204

Sum=4114

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

392

Download

761

Sum=1153

Nov 27, 2021 (publication date) through Jun 16, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Nov 27, 2021; 13(11): 1568-1583
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1568

Full Size Figure Download Figure

Figure 5 Schematic illustration of epigenetic modifications observed in hepatocellular carcinoma and chromatin modifiers targeted by epi-drugs. The figure represents general epigenetic alterations observed in hepatocellular carcinoma and different epigenetic modifiers that can be targeted via small molecule inhibitors. Moreover, DNA and chromatin mediated alterations observed in tumors are highlighted. Changes in DNA methylation and histone post-translational modifications levels inside normal cells lead to tumor formation. HCC: Hepatocellular carcinoma; HDM: Histone demethylase; HDAC: Histone deacetylase; HMT: Histone methyltransferase; DNMT: DNA methyltransferase; HAT: Histone acetyltransferase.

Citation: Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583
URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1568.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1568